ACE2 and COVID-19: Observing the limited expression of ACE2 in hepatic tissue, there remains a plausibility that any hepatic impairment in COVID-19 may be primarily not due to direct viral injury but indirect reasons, such as systemic hyper-inflammation, dysregulated immune response, and thrombosis of microvessels.